BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. today announced the pricing of its initial public offering of 10,000,000 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. In addition, Aimmune has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 shares of common stock at the same price. Aimmune's common stock is expected to begin trading on The NASDAQ Global Select Market on August 6, 2015 under the symbol AIMT.
The offering is expected to close on August 11, 2015, subject to satisfaction of customary closing conditions.
BofA Merrill Lynch, Credit Suisse and Piper Jaffray are acting as joint book-running managers for the offering.
A registration statement relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission on August 5, 2015. The offering of these securities is being made only by means of a prospectus, copies of which may be obtained from: BofA Merrill Lynch, Attention: Prospectus Department, 222 Broadway, New York, NY 10038, or by emailing [email protected]; Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, or by calling (800) 221-1037, or by emailing [email protected]; or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by calling (800) 503-4611, or by emailing [email protected]
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., founded in 2011 as Allergen Research Corporation (ARC), is a clinical-stage biopharmaceutical company developing treatments for peanut allergy and other food allergies. Aimmune Therapeutics' characterized oral desensitization immunotherapy (CODIT™) system, an approach to oral immunotherapy (OIT), uses rigorously characterized product candidates with gradual, controlled up-dosing protocols to obtain clinically meaningful desensitization to food allergens. Aimmune Therapeutics recently completed a Phase 2 study of its lead product, AR101, a complex mixture of naturally occurring proteins and pharmaceutical-grade ingredients for the treatment of peanut allergy, one of the most common food allergies.
Marissa Nakamichi, 323-202-1029